Endocare Inc

Endocare — CJS Securities Fifth Annual Conference January 2005

13 slides from Endocare's conference presentation, Jan 13, 2005

  1. Slide 1: Endocare, Inc. 2005 Outlook

    Slide 1: Endocare, Inc. 2005 Outlook

    CJS Securities Fifth Annual Conference New York, New York January 2005 Endocare, Inc. 2005 Outlook

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements, etc. Statements contained in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements

  3. Slide 3: Company Background

    Slide 3: Company Background

    Company Background Endocare is an innovative public medical device company focused on the development of minimally invasive technologies for tissue & tumor ablation and erectile dysfunction. The Company has a strong intellectual property position for its unique technologies that harnesses the powerf

  4. Slide 4: Mission

    Slide 4: Mission

    Mission Market - To become the leader in treating cancers and other conditions within various areas of the body through unique, innovative and cost effective cryoablation technologies Corporate - To restore and enhance our reputation and image with the public and with governmental regulatory agencie

  5. Slide 5: Endocare Executive Management

    Slide 5: Endocare Executive Management

    Endocare Executive Management Craig T. Davenport - CEO & Chairman - Chief Executive Officer since December 2003; Chairman since January 2004 - 1994 to 2003 CEO & Managing Partner of The D.W. Group Private investment company - 1985 to 1993 President & COO of Tokos Medical Corporation (NASDAQ) Medical

  6. Slide 6: Endocare Technology Groups

    Slide 6: Endocare Technology Groups

    Endocare Technology Groups Vacuum Technology Cryoablation Technology Erectile Dysfunction Urology Renal Cancer Prostate Cancer Radiology Oncology Kidney Tumors/Cancer Liver Tumors/Cancer Lung Tumors/Cancer Bone Pain

  7. Slide 7: Cryoablation Market Positioning

    Slide 7: Cryoablation Market Positioning

    Cryoablation Market Positioning Cryoablation provides an important tumor/tissue ablation modality with unique physician and patient benefits Long term proven efficacy (10 year liver and prostate, 5 year kidney) Broad applications - breast, lung, liver, kidney, bone, prostate Minimally invasive - tre

  8. Slide 8: Company Highlights

    Slide 8: Company Highlights

    Company Highlights Annual growth in procedures 35%+ in markets where overall penetration is less than 3%. Experienced management team. Clinically proven technology in prostate cancer with strong IP positioning and patent protection. $400 million+ growing market in prostate cancer. $750 million+ grow

  9. Slide 9: Q1 2005 - Objectives & Outlook

    Slide 9: Q1 2005 - Objectives & Outlook

    Q1 2005 - Objectives & Outlook Financial Establish Line of Credit with bank Complete capital fund raising Corporate Resolve SEC and DOJ investigations Complete National Security Exchange listing application process Procedures Continue historical, accelerated procedure growth of +35% Physicians Add 3

  10. Slide 10: Q2 2005 - Objectives & Outlook

    Slide 10: Q2 2005 - Objectives & Outlook

    Q2 2005 - Objectives & Outlook Financial Further reductions in cash use Continued margin improvement Corporate - Complete National Exchange listing process Procedures - Continue accelerated procedure growth of 35% or more Physicians Add 30+ new physicians (60 new physicians by the end of Q2) Marketi

  11. Slide 11: 2nd Half 2005 - Objectives & Outlook

    Slide 11: 2nd Half 2005 - Objectives & Outlook

    Procedures - Continue accelerated procedure growth of 35% or more Physicians Add 60+ new physicians for a total of 120+ new physicians in 2005 Marketing - Five (5) year Renal Cryoablation data published Initial findings of Mayo Cryo-bone study published Technology - Place numerous Cryocare CS System

  12. Slide 12: Endocare 2005 Outlook

    Slide 12: Endocare 2005 Outlook

    Unique clinically proven technology for tissue and tumor ablation with broad market potential and strong IP Rapid procedural growth in large expanding markets Accelerating market acceptance among physicians, academics, patients and payers Regulatory issues and problems will be resolved Gross margins

  13. Slide 13: THE END

    Slide 13: THE END

    THE END

Source: SEC EDGAR · 8-K filed Jan 13, 2005

More decks from Endocare Inc